Search

for
Search:

Learn

1 / 800 results

learn GT20029

Experimental topical drug designed to break down androgen receptors

What is GT20029 and how does it work as a topical anti-androgen for hair loss? GT20029 is an investigational topical androgen-receptor degrader. One 12-week Phase II trial in 180 Chinese men found two of four regimens beat placebo on hair count; it is not approved or available.
Is GT20029 more effective than finasteride or RU58841 for DHT-related hair loss? No trial has compared GT20029 with finasteride or RU58841. GT20029 is investigational, and RU58841 is an unapproved research chemical with no human safety data.
Are there any known side effects of using GT20029 on the scalp long-term? Long-term side effects are unknown. Trials of up to 12 weeks reported mostly mild scalp effects such as dryness and itching, at rates similar to placebo (Hu et al. 2025).
All 5 questions on GT20029 →

View more "g20029" in learn →

Research

5 / 21 results

research Methodologic considerations in evaluating early clinical outcomes of GT20029 for androgenetic alopecia

January 2026 in “Journal of Dermatological Treatment”

This source discusses a Phase 2 trial by Hu et al. that evaluated the efficacy of topical GT20029 compared to a placebo, though the abstract does not provide specific results.

research Efficacy and safety of topical GT20029 in male patients with androgenetic alopecia: a multicenter, randomized, double-blind, placebo-controlled phase 2 study

December 2025 in “Journal of Dermatological Treatment”

This randomized trial found that topical GT20029 significantly increased hair counts and width in Chinese men with androgenetic alopecia over 12 weeks, showing better results than placebo, with the 0.5% once daily and 1.0% twice weekly doses particularly effective.

research Efficacy and safety of topical GT20029 in male patients with androgenetic alopecia: a multicenter, randomized, double-blind, placebo-controlled phase 2 study

January 2025

In this multicenter Phase II trial, researchers found that topical GT20029 significantly increased hair regrowth in Chinese adult males with androgenetic alopecia compared to placebo, demonstrating good tolerability and suggesting the need for further studies to confirm its therapeutic potential.

research Efficacy and safety of topical GT20029 in male patients with androgenetic alopecia: a multicenter, randomized, double-blind, placebo-controlled phase 2 study

January 2025

This Phase II trial found that topical GT20029 significantly increased hair count and width at 12 weeks in Chinese men with androgenetic alopecia compared to placebo, with good tolerability and similar adverse event incidence across groups.

research Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions

9 citations , October 2025 in “MedComm”

This review discusses the development and clinical progression of PROTAC technology for targeted protein degradation, highlighting its potential to address previously "undruggable" targets but reports no new clinical results.

View more "g20029" in research →

Community Join

5 / 222 results

community Been off Tressless for a few years - what’s the latest on GT20029?

17 upvotes 1 month ago

GT20029 is an experimental topical treatment for male-pattern hair loss, showing promising results in Phase 2 trials and moving towards Phase 3. It aims to degrade androgen receptors in hair follicles, differing from treatments like finasteride and minoxidil.

community GT20029 Will Replace Finasteride For Hair Loss

58 upvotes 4 months ago

GT20029 shows promise as a topical treatment for hair loss, potentially replacing finasteride for some due to its low systemic exposure and ability to degrade androgen receptors. However, skepticism remains about its long-term efficacy and availability, with some users expressing doubt about new treatments consistently failing to reach the market.

community GT20029: How It Works for Hair Loss - Hair Loss “Cure”

38 upvotes 7 months ago

GT20029 is a potential treatment for androgenetic alopecia, addressing the root cause by targeting androgen receptors, unlike Minoxidil or Finasteride. It is seen as a preventative measure rather than a regrowth agent, with hopes for market release soon.

community GT20029 Big Phase 2 Update Results!

53 upvotes 9 months ago

GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.

community GT20029 Phase 2 results are out

in Treatment 60 upvotes 9 months ago

GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.

View more "g20029" in community →

Experts

— no results

Try a deeper search in experts →

Clinics

— no results

Try a deeper search in clinics →